In this article
- Understanding Lymphoma and the Challenge of Systemic Spread
- Effectiveness and Mechanism of Targeted Drug Therapy for Lymphoma
- Comprehensive Guide to Targeted Drugs by Lymphoma Type
- Understanding the Cost of Lymphoma Targeted Drug Treatment
- Lymphoma Risk Factors and Prevention Strategies
- How CancerFax Helps
The lymph in the human body is actually complicated. Lymphoma is the fastest and the highest death in malignant tumors, because the lymphatic system of the human body has a great effect on the whole body. Once cancer cells appear, they will spread along the blood, It will be spread all over the body, which makes the treatment more difficult. Lymphoma targeted drugs are not completely free of side effects. The patients who use them must carefully observe their changes bit by bit and communicate with the doctor in time to be able to reduce.
Early malignant lymphoma is actually lymphoma. When using targeted drugs, you must first perform genetic testing on the patient. When you find the corresponding targeted drugs, the targeted drugs have a direct killing effect on cancer cells. The advantage is that the damage to normal cells is not too great. Although there are side effects and drug resistance, it depends on the patient's physical function, good physical fitness, high immunity, and the best therapeutic effect. Therefore, patients with lymphoma have to find ways to improve their immune function and enhance their resistance to tumors while using targeted drugs.
Targeted drug therapy affects the biological processes of cells, acting in different ways, preventing cancer cells from growing or dividing, causing cancer cells to die or using their own immune system to help the body kill cancer cells. Compared with chemotherapy, targeted drugs can act more precisely on lymphoma cells and reduce the impact of treatment on healthy cells, thereby reducing the side effects of treatment while being more effective
Rituximab is the first targeted immunotherapy drug used to treat lymphoma. There are many other targeted drugs for the treatment of patients with lymphoma, some have been approved for marketing, and many drugs are still in clinical trials."
"1. Chronic lymphocytic leukemia (CLL) / small lymphocytic leukemia (SLL)
Ibrutinib (Ibutinib, Imbruvica Eke)
Idelalisib (Edelalis, Zydelig)
Obinutuzumab (Atoruzumab, Gazyva)
Rituximab (rituximab, Rituxan merova)"
"2. Skin (skin) T cell lymphoma
Brentuximab Vedotin (Bentuximab, Adcetris)"
"3. Diffuse large B-cell lymphoma
Rituximab (rituximab, Rituxan merova)"
"4. Follicular lymphoma
Idelalisib (Edelalis, Zydelig)
Obinutuzumab (Atoruzumab, Gazyva)
Rituximab (rituximab, Rituxan merova)
Ibritumomab Tiuxetan (Timobizumab, Zevalin)"
"5. Classic Hodgkin lymphoma
Brentuximab Vedotin (Bentuximab, Adcetris)
Nivolumab (Navuliu monoclonal antibody, Opdivo)
Pembrolizumab (Pambrolizumab, Keytruda)"
"6. Primary mediastinal B-cell lymphoma
Rituximab (rituximab, Rituxan merova)"
"7. Mantle cell lymphoma
Bortezomib (bortezomib, Velcade Velcade)
Ibrutinib (Ibutinib, Imbruvica Eke)
Lenalidomide (Lenalidomide, Revlimid)
Temsirolimus (for sirolimus, Torisel)"
"8. Systemic anaplastic large cell lymphoma
Brentuximab Vedotin (Bentuximab, Adcetris)
Lymphoma targeted drugs are mainly rituximab (rituximab injection), a course of treatment is about 10,000 or 20,000. The specific depends on the patient's own situation. If there is no drug resistance, you can continue to take it. If there are side effects or drug resistance, you need to suspend or use other treatment methods. Therefore, the price is not fixed. There will be changes.
The clean blood in the body is managed by the hematopoietic system, and the lymphatic system is the manager. There are many electronic products now, and radiation is everywhere, and there are virus infections that appear at any time. These are deadly lymphoma Incentives, you must pay more attention to staying away from lymphomas in life, and the choice of targeted drugs for lymphomas is not so random.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Related Articles
About CancerFax Editorial Team
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.